HK Stock Market Move | MP CARDIOFLOW-B (02160) dropped by 7%. It is recommended to consolidate stocks by 5 to 1, with the maintenance of 1000 shares per lot remaining unchanged.
Minimally Invasive HeartTransit-B (02160) fell by 7%, as of the time of publication, dropping by 7% to HK$0.93, with a turnover of HK$3,316,700.
MP CARDIOFLOW-B(02160) fell by 7%, falling to 0.93 Hong Kong dollars as of the time of publication, with a turnover of 3.3167 million Hong Kong dollars.
On the news front, on the evening of January 26, MicroPort CardioFlow announced that the board of directors recommends consolidating the company's share capital by combining existing issued and unissued shares at a ratio of 5 shares per share with a face value of 0.000005 US dollars to 1 share per share with a face value of 0.000025 US dollars. As of the announcement date, existing shares are traded in units of 1000 shares per hand on the Stock Exchange. After the share consolidation takes effect, the trading unit on the Stock Exchange will remain at 1000 shares of consolidated stock.
Related Articles
NIKE, Inc. Class B (NKE.US) has launched a new round of automation transformation, laying off 775 people at its distribution center in the United States in order to "streamline" the supply chain.
HK Stock Market Move | CSTONE PHARMA-B(02616) rose more than 4%, executive director Yang Jianxin once again increased holdings, accumulating nearly 12.48 million shares purchased.
HK Stock Market Move | KEYMED BIO-B(02162) increased by nearly 3%, its self-developed BCMACD3 bispecific antibody CM336 was granted FTD designation by the FDA.
NIKE, Inc. Class B (NKE.US) has launched a new round of automation transformation, laying off 775 people at its distribution center in the United States in order to "streamline" the supply chain.
HK Stock Market Move | CSTONE PHARMA-B(02616) rose more than 4%, executive director Yang Jianxin once again increased holdings, accumulating nearly 12.48 million shares purchased.
HK Stock Market Move | KEYMED BIO-B(02162) increased by nearly 3%, its self-developed BCMACD3 bispecific antibody CM336 was granted FTD designation by the FDA.
RECOMMEND
New Record Achieved As Spot Gold Tops $5,000 For The First Time; Institutions Set $6,600 Target
27/01/2026
117 Companies Raised Over HKD 285.6 Billion Through IPOs As Hong Kong Reclaims Global Leadership In 2025
27/01/2026
“A+H Hong Kong Listing Requires RMB 30 Billion Market Cap”? On‑Site Inquiry Dispels The Rumor
27/01/2026
